Manoj Eradath's questions to Zymeworks Inc (ZYME) leadership • Q4 2024
Question
Manoj Eradath, on behalf of Akash Tewari, asked about the delay in the HERIZON-GEA-01 trial readout, questioning if it was due to enrollment speed or event rates, and inquired about potential patient selection bias regarding PD-1 status.
Answer
Chair and CEO Kenneth Galbraith declined to speculate on the trial specifics, referring the question back to their partner Jazz Pharmaceuticals, who provided an update on the guidance and rationale during their own recent earnings call.